PRB2 and Rare hereditary thrombophilia: Between 1 March 2020 and 28 February 2022, 567 potential living liver donors underwent thrombophilia testing that included anti-thrombin (AT) III, protein S (PS), anti-phospholipid antibody (APLA), and protein C (PC).